Merck reports positive tulisokibart data: 16 analysts rate Merck & Co. stock Buy

Published on 10/05/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 5.10 percent to USD 16.61 billion in the second quarter of 2026. Merck & Co. stock costs EUR 128.74 on October 5, 2026 after EUR 127.96.

Soft watercolor illustration of an American pharmaceutical campus nestled in New Jersey autumn forests. Brick and glass research buildings with horizontal ribbon windows rise above golden and red maple trees. Wooded hills recede into a pale blue sky rende — Merck US58933Y1055 Campus-Aquarell: Herbstliche Pharma-Forschungsgebäude liegen tief eingebettet in den New-Jersey-Wäldern, weiche Pastelltöne, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) reported positive tulisokibart data on September 30, 2026, while 16 analysts rated Merck & Co. stock Buy and 11 rated it Hold. At Lang & Schwarz, the stock was trading at EUR 128.74 on October 5, 2026 at 9:01 a.m. CEST, up 0.61 percent versus the prior close of EUR 127.96.

Tulisokibart adds a clinical catalyst

According to FinanzNachrichten on September 30, 2026, Merck said its phase 2b study of tulisokibart met its primary and key secondary endpoints in patients with moderate to severe hidradenitis suppurativa. The result expands the clinical case for a therapy aimed at inflammatory diseases beyond Merck's established oncology portfolio.

The development is material because Merck's second-quarter 2026 revenue increased 5.10 percent year over year to USD 16.61 billion, according to the company's investor-relations page. The result puts operating performance and pipeline renewal on the same investor scorecard.

Revenue grows while earnings absorb charges

Merck's second-quarter 2026 net income attributable to common shareholders was a loss of USD 1.34 billion, while diluted earnings per share were a loss of USD 0.54. The figures reflect the financial impact of recent business-development activity and contrast with the company's revenue growth.

The company raised and narrowed its full-year 2026 revenue guidance to USD 66.30 billion to USD 67.30 billion, with adjusted earnings per share guidance of USD 2.66 to USD 2.76, according to Merck. Merck has also scheduled its third-quarter 2026 sales and earnings conference call for October 29, 2026.

Stock remains below its yearly high

Market data put Merck's market capitalization at USD 356.40 billion and its 52-week range at USD 82.01 to USD 156.92 as of October 2, 2026. The Lang & Schwarz euro quote is therefore closer to the upper end of the comparable dollar range than to its yearly low, although the currencies and venues are different.

According to MarketBeat on October 3, 2026, the analyst tally was 16 Buy ratings and 11 Hold ratings, with a consensus target of USD 145.76. That split leaves the pipeline evidence and the timing of new product growth central to how the market assesses Merck.

Merck stock price and next date

Merck & Co. stock was trading at EUR 128.74 at Lang & Schwarz on October 5, 2026 at 9:01 a.m. CEST, plus 0.61 percent versus the Lang & Schwarz prior close of EUR 127.96 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Merck stock.